BusinessPhoto: DCAT Value Chain InsightsBiopharma's Biggest Challenge Is Structural, Not Geopolitical
The biopharmaceutical industry's main challenge may stem from internal structural pressures on its innovation-driven model and the supporting biotech ecosystem, rather than from geopolitical disruptions. These structural issues could pose a deeper threat to the industry's future development and stability.
DCAT Value Chain Insights·


